
Nemaura Medical NMRD
Quarterly report 2023-Q4
added 02-12-2024
Nemaura Medical General and Administrative Expenses 2011-2026 | NMRD
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Nemaura Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.6 M | 6.17 M | 3.03 M | 2.77 M | 2.18 M | 915 K | 517 K | 511 K | 495 K | 202 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.17 M | 202 K | 2.24 M |
Quarterly General and Administrative Expenses Nemaura Medical
| 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.25 M | 1.56 M | 1.51 M | - | 1.23 M | 1.37 M | 1.27 M | - | 1.39 M | 4.15 M | 2.76 M | - | 582 K | 582 K | 1.37 M | 596 K | 543 K | 543 K | 655 K | 699 K | 490 K | 490 K | 525 K | - | 121 K | 238 K | 268 K | - | 108 K | 398 K | 290 K | - | 83.1 K | 281 K | 198 K | - | 16.8 K | 228 K | 211 K | - | 168 K | 171 K | 3.31 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.15 M | 3.31 K | 753 K |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Helius Medical Technologies
HSDT
|
9.27 M | $ 2.26 | 4.63 % | $ 1.37 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
AdaptHealth Corp.
AHCO
|
382 M | $ 13.03 | 1.8 % | $ 1.76 B | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
BioSig Technologies
BSGM
|
67.5 M | - | 37.08 % | $ 85.7 M | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
15.1 M | - | 1.37 % | $ 20.5 M | ||
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
LivaNova PLC
LIVN
|
549 M | $ 63.81 | -0.61 % | $ 3.48 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
LENSAR
LNSR
|
45.2 M | $ 5.1 | 0.2 % | $ 61 M | ||
|
Pulmonx Corporation
LUNG
|
101 M | $ 1.27 | 0.39 % | $ 51.7 M | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
Insulet Corporation
PODD
|
1.16 B | $ 190.15 | 0.31 % | $ 13.4 B | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.63 | 0.86 % | $ 39.2 M | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
5.9 M | $ 3.27 | 1.24 % | $ 122 M | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
ClearPoint Neuro
CLPT
|
16.5 M | $ 11.52 | -2.21 % | $ 326 M | ||
|
Globus Medical
GMED
|
1.18 B | $ 93.82 | -1.11 % | $ 12.7 B | ||
|
Sintx Technologies
SINT
|
6.2 M | $ 2.5 | 1.21 % | $ 6.93 M | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
Electromed
ELMD
|
39.3 M | $ 26.45 | -0.11 % | $ 224 M | ||
|
Second Sight Medical Products
EYES
|
1.11 M | - | -0.97 % | $ 54.4 M | ||
|
Stryker Corporation
SYK
|
8.65 B | $ 328.51 | 0.31 % | $ 126 B | ||
|
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | ||
|
Tactile Systems Technology
TCMD
|
88.7 M | $ 24.95 | -0.48 % | $ 571 M | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
TransMedics Group
TMDX
|
185 M | $ 109.0 | -1.74 % | $ 3.71 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
OrthoPediatrics Corp.
KIDS
|
120 M | $ 16.3 | 0.65 % | $ 382 M | ||
|
Butterfly Network
BFLY
|
39.8 M | $ 5.38 | 0.94 % | $ 1.14 B | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
Varex Imaging Corporation
VREX
|
133 M | $ 12.49 | -0.32 % | $ 517 M | ||
|
Delcath Systems
DCTH
|
43.5 M | $ 10.99 | 1.38 % | $ 394 M | ||
|
IRIDEX Corporation
IRIX
|
7.73 M | $ 1.09 | 2.83 % | $ 18.5 M | ||
|
CONMED Corporation
CNMD
|
132 M | $ 39.54 | 3.13 % | $ 1.23 B | ||
|
Inspire Medical Systems
INSP
|
625 M | $ 55.85 | -0.82 % | $ 1.64 B | ||
|
Integer Holdings Corporation
ITGR
|
212 M | $ 84.93 | -1.27 % | $ 2.95 B | ||
|
PAVmed
PAVM
|
16.2 M | $ 8.81 | -2.11 % | $ 5.91 M | ||
|
Invacare Corporation
IVC
|
227 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
2.09 B | $ 83.67 | -0.57 % | $ 48.9 B |